Principal Scientist
Genentech Inc.
Ran Li is a Principal Scientist in the Development Science organization at Genentech. Ran’s expertise is in applying translational pharmacokinetics and pharmacodynamics principles, as well as computational modeling and simulation approaches, to guide the preclinical development and clinical candidate selection of antibody-based therapeutics. Specifically, Ran is experienced in developing PKPD model to understand dose/efficacy/toxicity relationships, to translate PKPD relationships between different preclinical species, and to predict human PK and dose using preclinical animal models. Ran supports drug development programs in multiple therapeutic areas, including oncology, immunology, and cancer immunotherapies. Ran is also the author of 31 scientific publications (10 as first-author).
Prior to joining the Genentech, Ran received his postdoctoral training at the Massachusetts General Hospital and Harvard Medical School. His postdoctoral research focused on understanding the molecular mechanisms governing PK/PD and ADME of various therapeutics (albumin-bound drugs, antibodies, nanomedicines, and small molecule kinase inhibitors) using mouse tumor models, in vivo imaging, single-cell techniques, and computational modeling. Prior to his postdoctoral training, Ran obtained his Ph.D. in Biological Engineering from Massachusetts Institute of Technology, where he focused on using organ-on-a-chip platforms to study drug delivery, cancer cell-immune cell interactions, and mechanobiology.